Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
BMY logo

BMS Growth Portfolio Surges as Revlimid Revenue Plummets 49%

BMY10-KFiling Date: 2/11/2026
Bristol Myers Squibb Company
Description

What this story covers

Bristol Myers Squibb is navigating a critical transition, using a 68% surge in new cell therapy sales to offset massive generic erosion of legacy blockbusters. The company faces intensifying pressure from U.S. drug price negotiations starting in 2026.

Story snapshot

CompanyBristol Myers Squibb Company
TickerBMY
VariantStandard detailed
Duration11:12
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000014272-26-000004
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in